Patrys Limited (ASX:PAB)
Australia · Delayed Price · Currency is AUD 0.0450
+0.0030 (7.14%)
May 29, 2026, 3:47 PM AEST
Patrys Revenue
Patrys had revenue of 2.30K AUD in the half year ending December 31, 2025, a decrease of -99.66%. This brings the company's revenue in the last twelve months to 100.38K, down -93.10% year-over-year. In the fiscal year ending June 30, 2025, Patrys had annual revenue of 828.54K, down -40.57%.
Revenue (ttm)
100.38K
Revenue Growth
-93.10%
P/S Ratio
298.85
Revenue / Employee
10.04K
Employees
10
Market Cap
30.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 828.54K | -565.62K | -40.57% |
| Jun 30, 2024 | 1.39M | -1.46M | -51.11% |
| Jun 30, 2023 | 2.85M | -481.67K | -14.45% |
| Jun 30, 2022 | 3.33M | 2.00M | 149.08% |
| Jun 30, 2021 | 1.34M | 565.53K | 73.18% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Neurotech International | 7.07M |
| Neurizon Therapeutics | 5.98M |
| Imugene | 3.94M |
| Noxopharm | 3.40M |
| Proteomics International Laboratories | 3.21M |
| Entropy Neurodynamics | 1.58M |
| Avecho Biotechnology | 1.24M |